泊那替尼与贝林妥欧单抗同步联合治疗费城染色体阳性急性淋巴细胞白血病的结果
本文更新了无化疗方案贝林妥欧单抗联合泊那替尼治疗60例新诊断费城染色体阳性急性淋巴细胞白血病患者的经验。中位随访24个月时,完全分子学缓解率为83%,二代测序微小残留病阴性率为98%,估计3年总生存率为91%、无事件生存率为77%。
要点
- 中位随访24个月,完全分子学缓解率83%,二代测序微小残留病阴性率98%。
- 估计3年总生存率91%,无事件生存率77%,仅2例患者接受造血干细胞移植。
- 7例患者复发,其中4例为孤立性中枢神经系统复发。
核心结论
- 泊那替尼与贝林妥欧单抗同步联合方案是一种高效且相对安全的无化疗方案,可减少多数患者对强化化疗和首次缓解期造血干细胞移植的需求。
研究设计与样本
- 本文为临床试验更新分析,报告60例新诊断费城染色体阳性急性淋巴细胞白血病患者接受贝林妥欧单抗联合泊那替尼无化疗方案的经验。
主要发现
- 中位随访24个月,逆转录聚合酶链反应检测的完全分子学缓解率为83%,其中第一疗程结束时为67%。
- 二代克隆测序检测的微小残留病阴性率为98%,其中第一疗程结束时为45%。
- 仅2例患者接受造血干细胞移植;7例患者复发,其中2例为全身性复发、4例为孤立性中枢神经系统复发、1例为髓外费城染色体阴性CRLF2阳性前B急性淋巴细胞白血病。
- 估计3年总生存率为91%,无事件生存率为77%。
- 3例患者因不良事件停用贝林妥欧单抗(相关1例,不相关2例);9例患者停用泊那替尼,原因包括脑血管缺血、冠状动脉狭窄、持续性皮疹、肝功能检查升高伴药物性脂肪肝、心房血栓、下肢严重动脉闭塞性疾病、胸膜心包积液和衰弱。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.In this analysis, we update our experience with the chemotherapy-free regimen of blinatumomab and ponatinib in 60 patients with newly diagnosed Philadelphia chromosome (Ph)-positive ALL. At a median follow-up of 24 months, the complete molecular response rate by reverse transcriptase-polymerase chain reaction was 83% (67% at the end of course one), and the rate of measurable residual disease negativity by next-generation clono-sequencing was 98% (45% at the end of course one). Only two patients underwent hematopoietic stem cell transplantation (HSCT). Seven patients relapsed: two with systemic disease, four with isolated CNS relapse, and one with extramedullary Ph-negative, CRLF2-positive pre-B ALL. The estimated 3-year overall survival rate was 91% and event-free survival rate was 77%. Three patients discontinued blinatumomab because of adverse events (related, n = 1; unrelated, n = 2) and nine discontinued ponatinib because of cerebrovascular ischemia, coronary artery stenosis, persistent rash, elevated liver function tests with drug-induced fatty liver, atrial thrombus, severe arterial occlusive disease of lower extremities, pleuro-pericardial effusion, and debilitation. In conclusion, the simultaneous combination of ponatinib and blinatumomab is a highly effective and relatively safe nonchemotherapy regimen. This regimen also reduces the need for intensive chemotherapy and HSCT in first remission in the majority of patients.
引用
- Kantarjian H, Short NJ, Haddad FG, et al. Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL. J Clin Oncol. 2024. PMID: 39028925. doi:10.1200/JCO.24.00272
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。